T-cell receptors have been engineered on viral capsids to target cancer cells.
Recent advancements in immunotherapy demonstrate that viral capsids and virus-like particles can be engineered to deliver receptor-based constructs like CARs to target cancer cells.
The provided papers (specifically papers 0 and 2) discuss the use of viral vectors, viral-like particles, and capsid engineering to deliver chimeric antigen receptors (CARs) and other immunotherapeutic payloads for targeted cancer treatment. The claim is well-supported by these findings.
Viral capsids and virus-like particles can be engineered to deliver receptor-based constructs to target cancer cells.
Wang R, Yu J, Caligiuri MA, Ma S. Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.. 2026. https://doi.org/10.1158/0008-5472.can-25-3748
Discusses viral vectors and viral-like particles engineered for in vivo CAR T-cell delivery and targeting.
See more details
Xiao Y, Bai M, Ang MJY, Mitchell MJ, Han X. Transient T cell therapies.. 2026. https://doi.org/10.1016/bs.apha.2026.05.007
Mentions engineered virus-like particles used for delivering transient CAR therapies in situ.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt